Versartis Reaches New 52-Week High at $36.86 (VSAR)
Shares of Versartis (NASDAQ:VSAR) hit a new 52-week high during trading on Friday , Analyst Ratings News reports. The company traded as high as $36.86 and last traded at $34.00, with a volume of 29,497 shares. The stock had previously closed at $31.88.
A number of analysts have recently weighed in on VSAR shares. Analysts at Zacks initiated coverage on shares of Versartis in a research note on Wednesday, April 23rd. They set a “hold” rating on the stock. Separately, analysts at Cowen and Company initiated coverage on shares of Versartis in a research note on Tuesday, April 15th. They set an “outperform” rating and a $45.00 price target on the stock. Finally, analysts at Canaccord Genuity initiated coverage on shares of Versartis in a research note on Tuesday, April 15th. They set a “buy” rating and a $36.00 price target on the stock. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Versartis currently has a consensus rating of “Buy” and a consensus target price of $55.00.
The stock has a 50-day moving average of $29.14 and a 200-day moving average of $28.85. The company’s market cap is $792.0 million.
Versartis (NASDAQ:VSAR) last posted its quarterly earnings results on Monday, May 5th. The company reported ($2.57) earnings per share for the quarter, beating the analysts’ consensus estimate of ($6.37) by $3.80. On average, analysts predict that Versartis will post $-11.18 earnings per share for the current fiscal year.
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is initially developing its long-acting recombinant human growth hormone, VRS-317, for growth hormone deficiency (NASDAQ:VSAR), an orphan disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.